Development of in vitro and in vivo c-Met targeted dual-modal nanoprobes for NIR II fluorescent bioimaging and magnetic resonance imaging of breast carcinoma metastasis

Abstract

Because of the conventional bioimaging methods, including ultrasound and X-ray examinations often lack accuracy and sensitivity in the early diagnosis, as a heterogeneous subtype of breast cancer, it remains an urgent need to develop efficaciously and sensitively diagnostic drivers of triple negative breast cancer (TNBC). The overexpression of c-mesenchymal epithelial transition-factor (c-Met) is associated with the basal subtype of breast carcinoma and linked with decreased survival rate of TNBC patients. Here, we have synthesized a dual-modal nanoprobe with luminescence imaging in the bio-window of near infrared II region (NIR II, 1000–1700) and magnetic resonance imaging (MRI) performances. After c-Met targeting binding protein decoration, this Fe3O4@mSiO2-ICG/cMBP had outstanding size stability and preeminent biocompatibility. Meaningfully, it presented effective TNBC cells recognition in vitro. Besides, after caudal-vein injection of this nanoprobe, both NIR II luminescence imaging and MRI demonstrated that it can more efficiently concentrated in metastatic TNBC tumors in comparison with Fe3O4@mSiO2-ICG and clinical used Gd-DTPA. Meanwhile, the core–shell nanoprobes also showed negligible toxicity in vivo. All results suggested that our cMBP modified nanocomposite could provide a fascinating and efficient non-invasive diagnostic tool for TNBC detection in clinic.

Keywords

• c-Met binding polypeptides (cMBP)
• TNBC diagnosis
• Fe3O4
• NIR II fluorescent imaging
• MRI